<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35098820</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for <i>H. pylori</i> infection in Sichuan areas.</ArticleTitle>
        <Pagination>
          <StartPage>426</StartPage>
          <EndPage>435</EndPage>
          <MedlinePgn>426-435</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2031269</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of high-dose amoxicillin-proton pump inhibitor dual therapy, and to provide a new eradication regimen as a first-line option for patients with <i>H. pylori</i> infection.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 971 <i>H. pylori</i> positive patients who received initial treatment were recruited from March to August 2020, and randomly divided into treatment group and control group. The treatment group received of 20 mg esomeprazole four times daily and 750 mg amoxicillin four times daily for 14 days. Control group received of 220 mg bismuth potassium citrate twice daily, 20 mg esomeprazole twice daily, 1000 mg amoxicillin twice daily and 250 mg clarithromycin capsule twice daily for 14 days. Four weeks after the end of treatment, the urea breath test was reviewed to detect whether <i>H. pylori</i> was eradicated.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no statistical differences in age, gender, the total clinical symptom scores before and after initial treatment, the compliance, and the degree of remission of symptoms before and after initial treatment between the two groups. The eradication rates of <i>H. pylori</i> between dual therapy and quadruple therapy were 88.31% and 85.26% (<i>p</i>=.158) by intention-to-treat (ITT) analysis, 88.66% and 85.44% (<i>p</i>=.186) by modified intention-to-treat (mITT) analysis, and 91.63% and 90.60% (<i>p</i>=.116) by PP analysis, respectively. Adverse events in dual therapy group were significantly lower than quadruple therapy group (13.3% vs. 28.2% (<i>p</i>&lt;.01)).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For the initial treatment of <i>H. pylori</i> infection, the high-dose dual therapy regimen has the same efficacy as the bismuth-containing quadruple therapy regimen, good compliance, less adverse reactions and high safety, so it can be recommended as the empirical first-line treatment regimen for the eradication of <i>H. pylori</i> (KY2019173).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Changping</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Muhan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Xiaosong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Provincial People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Caiping</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Provincial People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liangping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Provincial People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>First People's Hospital of Liangshan Yi Autonomous Prefecture, Xichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan University West China Hospital Tibet People's Government in Chengdu Office Branch, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan University West China Hospital Tibet People's Government in Chengdu Office Branch, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Sijing</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Medical College Second Affiliated Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Medical College Second Affiliated Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Shunbin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>People's Hospital of Deyang City, Deyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>People's Hospital of Deyang City, Deyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Suining Central Hospital, Suining, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jianyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Suining Central Hospital, Suining, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Mingyong</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Science City Hospital, Mianyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Haiyan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Bazhong Central Hospital, Bazhong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Peijie</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth People's Hospital of GuangYuan, GuangYuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xiaoyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Second People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jian</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Second People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shan</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Third People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Chengdu Fifth People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zonghua</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>The Second People's Hospital of Yibin, West China Hospital of Sichuan University, Yibin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Xuejie</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>People's Hospital of Leshan, Leshan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Leshan City Geriatric Hospital, Leshan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Lijuan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Leshan Sichuan Armed Police General Hospital, Leshan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Xianfei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Leshan Sichuan Armed Police General Hospital, Leshan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Pengzhou People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Shaoya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Anyue County People's Hospital, Ziyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Anyue County People's Hospital, Ziyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Zigong Third People's Hospital, Zigong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hairong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Zigong Third People's Hospital, Zigong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Yuquan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>First Peoples Hospital of Neijiang, Neijiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The First People's Hospital of Ziyang, Ziyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Jiangang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Wuhou District Third People's Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Multi-Center Clinical Research Collaboration Group of Sichuan Provincial H. pylori Scientific Group, Sichuan Provincial Medical Association</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>804826J2HU</RegistryNumber>
          <NameOfSubstance UI="D000658">Amoxicillin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000658" MajorTopicYN="N">Amoxicillin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016481" MajorTopicYN="Y">Helicobacter Infections</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016480" MajorTopicYN="Y">Helicobacter pylori</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">H. pylori</Keyword>
        <Keyword MajorTopicYN="Y">amoxicillin</Keyword>
        <Keyword MajorTopicYN="Y">dual therapy</Keyword>
        <Keyword MajorTopicYN="Y">initial treatment</Keyword>
        <Keyword MajorTopicYN="Y">proton pump inhibitor</Keyword>
      </KeywordList>
      <CoiStatement>There is no interest between all the authors in this article, ranking disputes, all authors agree to publish papers in the magazine, no copyright disputes.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35098820</ArticleId>
        <ArticleId IdType="pmc">PMC8812792</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2031269</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lee YC, Chen TH, Chiu HM, et al. . The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3618687</ArticleId>
            <ArticleId IdType="pubmed">22698649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan W, Yumin L, Kehu Y, et al. . 
Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45(6):665–676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20201716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franceschi F, Tortora A, Gasbarrini G, et al. . Helicobacter pylori and extragastric diseases. Helicobacter. 2014;19(Suppl. 1):52–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25167946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malfertheiner P, Megraud F, O'Morain CA, et al. . Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27707777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fallone CA, Chiba N, van Zanten SV, et al. . 
The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27102658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Xie Y, Lu H.. 
The fifth national consensus report on the treatment of H. pylori infection. Gastroenterology. 2017;22(6):346–360.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang B, Lv ZF, Wang YH, et al. . Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014;20(40):14973–14985. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4209562</ArticleId>
            <ArticleId IdType="pubmed">25356059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YX, Zhou LY, Song ZQ, et al. . Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21(9):2786–2792. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4351232</ArticleId>
            <ArticleId IdType="pubmed">25759550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graham DY, Javed SU, Keihanian S, et al. . 
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010;45(8):816–820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20195646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, Luo L, Long X, et al. . High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019;24(4):e12596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31111580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JC, Lin CJ, Wang HL, et al. . High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905.e5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4404168</ArticleId>
            <ArticleId IdType="pubmed">25460556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao CP, Xiao X, Liu PX, et al. . 
High-dose amoxicillin/esomeprazole dual therapy as a first-line therapy for H. pylori eradication. World Chin J Digestol. 2018; 26(6):353–359.</Citation>
        </Reference>
        <Reference>
          <Citation>Song Z, Zhou L, Xue Y, et al. . A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25(6):e12762. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33040439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Zhang Y, Fan L, et al. . 
Correction: eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114(5):835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30946040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao CP, Zhang D, Zhang T, et al. . PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32314468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39(3):465–480. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20951912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamboj S, Gupta GD, Kamboj S, et al. . 
Citric acid as an effective release retarding agent in matrix tablets formulation. World J Eng. 2010;7(Suppl. 3):527–528.</Citation>
        </Reference>
        <Reference>
          <Citation>Furuta T, Shirai N, Kodaira M, et al. . 
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81(4):521–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17215846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim GH.
Proton pump inhibitor-related gastric mucosal changes. Gut Liver. 2020;15(5):646–652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8444106</ArticleId>
            <ArticleId IdType="pubmed">32327613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou HY, Chang CC, Sheu MT, et al. . 
Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65(1):55–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18751689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugimoto M, Furuta T, Shirai N, et al. . 
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004;76(4):290–301. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15470328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahara S, Sugimoto M, Uotani T, et al. . 
Potent gastric acid inhibition over 24 hours by 4-times daily dosing of esomeprazole 20 mg. Digestion. 2015;91(4):277–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25924819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zullo A, Ridola L, Francesco VD, et al. . 
High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28(4):448–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4585390</ArticleId>
            <ArticleId IdType="pubmed">26423014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhu YJ, Zhao Z, et al. . Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol. 2020;32(5):563–568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31851093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tai WC, Liang CM, Kuo CM, et al. . 
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-H. pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718–1724. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30768161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren L, Lu H, Li HY, et al. . 
New dual therapy for primary treatment of H. pylori infection: a prospective randomized study in Shanghai, China. J Dig Dis. 2014;15(11):622–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25205201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki S, Gotoda T, Kusano C, et al. . Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–1026. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7282559</ArticleId>
            <ArticleId IdType="pubmed">31915235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y.
Analysis of 23SrRNA gene mutations associated with drug resistance and clarithromycin resistance of Helicobacter pylori in South Sichuan. Luzhou: Southwest Medical University; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. . Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015;21(4):1305–1314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4306177</ArticleId>
            <ArticleId IdType="pubmed">25632206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Öztürk K, Kurt Ö, Çelebi G, et al. . High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol. 2020;31(3):234–238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7197926</ArticleId>
            <ArticleId IdType="pubmed">32343235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Echizen H.
The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26369775</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
